These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23733004)

  • 1. The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users.
    De Vos AS; Kretzschmar ME
    J Theor Biol; 2013 Sep; 333():126-34. PubMed ID: 23733004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users.
    de Vos AS; van der Helm JJ; Prins M; Kretzschmar ME
    Epidemics; 2012 Jun; 4(2):57-67. PubMed ID: 22664064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
    AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users.
    Kretzschmar M; Wiessing L
    AIDS; 2008 Aug; 22(13):1527-37. PubMed ID: 18670211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India.
    Mahanta J; Medhi GK; Paranjape RS; Roy N; Kohli A; Akoijam BS; Dzuvichu B; Das HK; Goswami P; Thongamba G;
    AIDS; 2008 Dec; 22 Suppl 5():S59-68. PubMed ID: 19098480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
    Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
    J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?
    de Vos AS; Prins M; Kretzschmar ME
    Addiction; 2015 Jun; 110(6):975-83. PubMed ID: 25586171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study.
    Sutton AJ; Hope VD; Mathei C; Mravcik V; Sebakova H; Vallejo F; Suligoi B; Brugal MT; Ncube F; Wiessing L; Kretzschmar M
    J Viral Hepat; 2008 Nov; 15(11):809-16. PubMed ID: 18761605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project.
    Caiaffa WT; Mingoti SA; Proietti FA; Carneiro-Proietti AB; Silva RC; Lopes AC; Doneda D
    J Urban Health; 2003 Mar; 80(1):106-14. PubMed ID: 12612100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India.
    Basu D; Sharma AK; Gupta S; Nebhinani N; Kumar V
    Indian J Med Res; 2015 Sep; 142(3):311-6. PubMed ID: 26458347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
    Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
    Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of hepatitis C virus treatment: a balance of preventing onward transmission and re-infection.
    de Vos AS; Kretzschmar ME
    Math Biosci; 2014 Dec; 258():11-8. PubMed ID: 25242609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
    Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
    Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
    PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
    Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil.
    Oliveira Mde L; Bastos FI; Telles PR; Hacker Mde A; Oliveira SA; Miguel JC; Yoshida CF
    J Clin Virol; 2009 Mar; 44(3):200-6. PubMed ID: 19195927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
    Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
    Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.